Vienna, Austria played host to a momentous gathering, welcoming over 15,000 attendees from across five continents for the ...

Favorable safety and tolerability, particularly when compared to standard of care biologics or JAKs Max response rates have not yet been observed; strict continuation criteria at three months in this ...

Respiratory Syncytial Virus or RSV is one of the most common respiratory viruses circulating today. Often thought of as only being dangerous to babies and toddlers due to how often child-related ...

Last winter’s respiratory syncytial virus, or RSV, season wasn’t as brutal for U.S. babies. A new study suggests two preventive tools — a maternal vaccine and a monoclonal antibody for ...

Far fewer babies went to the hospital struggling to breathe from RSV, a severe respiratory infection, after the debut of a new vaccine and treatment this season, according to an analysis published ...

Respiratory syncytial virus (RSV)–associated hospitalization rates among infants in the United States were significantly lower in the first year when prevention products were widely available ...

RSV prevention products led to a significant reduction in hospitalization rates for infants aged 0 to 7 months during the 2024-2025 season. The maternal RSV vaccine and nirsevimab were key ...

Get Instant Summarized Text (Gist) Widespread use of maternal RSV vaccination and nirsevimab during the 2024–2025 season was linked to significant reductions in RSV-associated hospitalizations ...

Saskatchewan is expanding its infant RSV immunization program to include all babies born one month before and during RSV season, which typically lasts from the start of October until the end of ...

But a rise in hospitalizations among slightly older children — still at risk but too old to be eligible for the products — shows the decline occurred in the context of a severe RSV season.

Among 69 hospitalisations of infants for respiratory syncytial virus (RSV)–related lower respiratory tract infection (LRTI) in a Spanish study, 65.2% occurred despite the administration of ...

Nirsevimab associated with lower odds of RSV-related hospitalization, ICU admission, lower respiratory tract infection incidence. HealthDay News — Nirsevimab is effective for reducing the burden ...